Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Anke Pagnon"'
Autor:
Anke Pagnon, Christophe Carre, Marion Aguirre, Emilie Chautard, Sophie Gimenez, Franck Raynal, Emmanuel Feroldi, Paul Scott, Kayvon Modjarrad, Manuel Vangelisti, Nathalie Mantel
Publikováno v:
EBioMedicine, Vol 108, Iss , Pp 105332- (2024)
Summary: Background: Yellow fever (YF), a mosquito-borne acute viral haemorrhagic illness, is endemic to many tropical and subtropical areas of Africa and Central and South America. Vaccination remains the most effective prevention strategy; however,
Externí odkaz:
https://doaj.org/article/2a2747ae42384d60b9b6678996455730
Autor:
Sarah Begue, Gwenn Waerlop, Bruno Salaun, Michel Janssens, Duncan Bellamy, Rebecca Jane Cox, Richard Davies, Elena Gianchecchi, Donata Medaglini, Emanuele Montomoli, Elena Pettini, Geert Leroux-Roels, Frédéric Clement, Anke Pagnon
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Despite the knowledge that cell-mediated immunity (CMI) contributes to the reduction of severe influenza infection, transmission, and disease outcome, the correlates of protection for cell-mediated immunity remain still unclear. Therefore, measuring
Externí odkaz:
https://doaj.org/article/c403b38c5ac8489a863b3b4df632aebc
Autor:
Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Hao Wang, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe, Frederique Jantet-Blaudez, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 2107-2116 (2021)
The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who comp
Externí odkaz:
https://doaj.org/article/01e9265349dd42e8983c677b9b6022e8
Autor:
Stephen C De Rosa, Kristen W Cohen, Matthew Bonaparte, Bo Fu, Sanjay Garg, Catherine Gerard, Paul A Goepfert, Ying Huang, Daniel Larocque, M. Juliana McElrath, Daryl Morris, Robbert Van der Most, Guy deBruyn, Anke Pagnon
Publikováno v:
Clinical & Translational Immunology, Vol 11, Iss 1, Pp n/a-n/a (2022)
Abstract Objectives We previously described the Phase I‐II evaluation of SARS‐CoV‐2 recombinant protein candidate vaccine, CoV2‐PreS‐dTM, with AF03‐ or AS03‐adjuvant systems (ClinicalTrials.gov, NCT04537208). Here, we further characteri
Externí odkaz:
https://doaj.org/article/a1cfa23ff2034272811b6634993dec22
Autor:
Lynette Pei-Chi Shek, May-Lin Helen Oh, Matthew Bonaparte, Hao Wang, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon, Juliana Park, Frédérique Jantet-Blaudez, Sophia Archuleta, Alain Bouckenooghe, Carina Frago
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7676baa81ef947c4866817a6ecdc890b
http://europepmc.org/articles/PMC8189141
http://europepmc.org/articles/PMC8189141
Autor:
Danielle Salha, Marin Ming, Nidhi Kapoor, Kimberley Williams, Pappachan E. Kolattukudy, Beata Gajewska, Lidice Bernardo, Fabienne Piras, Leslie G. Chan, Anke Pagnon, Jin Su, Lucy Gisonni-Lex
Publikováno v:
Vaccine. 37:2960-2966
Potency assays for vaccine products are an important regulatory requirement, and are used to assess product quality and consistency prior to lot release for clinical testing. Ideally they measure an established correlate of efficacy or protection. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a81de2829421d2fd34e21738c6ccab4b
https://doi.org/10.1016/j.vaccine.2019.04.035
https://doi.org/10.1016/j.vaccine.2019.04.035
Autor:
José Luis Arredondo-García, Doris Maribel Rivera, Ana Paula Perroud, Luis Andrey Rojas Peñalosa, Betzana Zambrano, Margarita Cortés, Gustavo H. Dayan, Fernando Noriega, Reynaldo Dietze, Carlos A. DiazGranados, Frédérique Jantet-Blaudez, Enid J Garcia-Rivera, Anke Pagnon, Hao Wang, Matthew Bonaparte, Diana Coronel
Publikováno v:
The Pediatric infectious disease journal. 39(10)
Background We previously described an increased immune response 28 days after a booster dose of the live, attenuated, tetravalent dengue vaccine (CYD-TDV) in healthy adolescents and adults in Latin America (CYD64, NCT02623725). This follow-up study e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7164e182d8eec797898b85673ea48795
https://pubmed.ncbi.nlm.nih.gov/32932330
https://pubmed.ncbi.nlm.nih.gov/32932330
Autor:
Jean Lang, Nathalie Mantel, Veronique Barban, Aymeric de Montfort, Florence Boudet, Fabrine Pradezynski, Anke Pagnon
Publikováno v:
Journal of Virology
Recent data obtained with the live-attenuated tetravalent dengue CYD-TDV vaccine showed higher protective efficacy against dengue virus type 4 (DENV-4) than against DENV-2. In contrast, results from previous studies in nonhuman primates predicted com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::064aba3d0fb023c6575ce764f2752af1
http://europepmc.org/articles/PMC5974474
http://europepmc.org/articles/PMC5974474